Company: SHPH
Filing Date: 2025-01-24
Form Type: 424B3
Source: 0001493152-25-003508
Chunk: 54

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-24
Form: 424B3
Chunk 54
---
 apply to the Company’s audits unless the SEC determines otherwise.                                                            |

| ● | The                                                                                                                                        
 JOBS Act amended Section 7(a) of the Securities Act to provide that the Company need not present more than two years of audited            
 financial statements in an initial public offering registration statement and in any other registration statement, need not present        
 selected financial data pursuant to Item 301 of Regulation S-K for any period prior to the earliest audited period presented in connection 
 with such initial public offering. In addition, the Company is not required to comply with any new or revised financial accounting         
 standard until such date as a private company (i.e., a company that is not an “issuer” as defined by Section 2(a) of                       
 Sarbanes-Oxley) is required to comply with such new or revised accounting standard. Corresponding changes have been made to the Exchange   
 Act, which relates to periodic reporting requirements, which would be applicable if the Company were required to comply with them.         |

| ● | As                                                                                                                                     
 long as we are an EGC, we may comply with Item 402 of Regulation S-K, which requires extensive quantitative and qualitative disclosure 
 regarding executive compensation, by disclosing the more limited information required of a “smaller reporting company.”                |

| 37 |

| ● | The                                                                                                                                 
 JOBS Act will also exempt us from the following additional compensation-related disclosure provisions that were imposed on          
 U.S. public companies pursuant to the Dodd-Frank Act: (i) the advisory vote on executive compensation required by Section 14A(a)    
 of the Exchange Act; (ii) the requirements of Section 14A(b) of the Exchange Act relating to stockholders advisory votes on “golden 
 parachute” compensation; (iii) the requirements of Section 14(i) of the Exchange Act as to disclosure relating to the relationship  
 between executive compensation and our financial performance; and (iv) the requirement of Section 953(b)(1) of the Dodd-Frank Act,  
 which requires disclosure as to the relationship between the compensation of our chief executive officer and median employee pay.   |

Our stock price may be volatile, and purchasers of our common stock could incur substantial losses.

Since commencement of trading on Nasdaq Stock Market LLC or Nasdaq, on August 29, 2022, our stock price has been extremely volatile, having traded as high as $1,010.08 and as low as $0.58. As a result of this volatility, investors may not be able to